Merck, Eisai Report Yet Another Failure For Keytruda Plus Lenvima Combo Trial, This Time In Endometrial Cancer
Portfolio Pulse from Vandana Singh
Merck & Co Inc (MRK) and Eisai Co Ltd (ESALY, ESALF) announced the Phase 3 LEAP-001 trial of Keytruda plus Lenvima did not meet primary endpoints for treating advanced or recurrent endometrial carcinoma. This follows previous trial failures in lung cancer and melanoma. However, a trial in renal cell carcinoma showed a benefit. MRK shares saw a slight premarket increase.
December 08, 2023 | 1:26 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Eisai's collaboration with Merck on the Keytruda-Lenvima combo faced a setback with the trial failure in endometrial cancer, potentially impacting its stock.
The trial failure is directly related to Eisai's product in collaboration with Merck, which could negatively affect investor sentiment and the stock price in the short term.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
Eisai's collaboration with Merck on the Keytruda-Lenvima combo faced a setback with the trial failure in endometrial cancer, potentially impacting its stock.
The trial failure is directly related to Eisai's product in collaboration with Merck, which could negatively affect investor sentiment and the stock price in the short term.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
NEUTRAL IMPACT
Merck's Keytruda-Lenvima combo failed in a Phase 3 trial for endometrial cancer, adding to previous trial failures. Despite this, MRK shares increased slightly premarket.
The failure of the LEAP-001 trial is negative news, but the slight premarket increase in MRK shares suggests that the market may have anticipated this outcome or is focusing on other positive aspects of the company.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80